News Sentiment

KRYS sentiment intelligence

Krystal Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 348.06 Week of 19 Jun 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+9.5% over one week, +16.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 9.5% Price confirming higher
Trend fit Trend active 16.2% over four weeks
Fair value 96.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 26
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
simplywall.st 7
Simply Wall Street 5
TradingKey 5
Stock Titan 4
TradingView 3
Investing.com 2
DirectorsTalk Interviews 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 22
Analyst action 4
Regulatory and legal 2
Balance sheet 2
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Simply Wall Street Direct company coverage

Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels

Krystal Biotech (KRYS) has seen its institutional ownership surge to a sector-leading score of 10.00, with major investors like ETHSX and BlackRock increasing their holdings by 11.17% quarter-over-quarter. This heightened professional investor interest comes as the company's P/E

Tone
Positive 70/100
Event
Market update
Published
22 Jun 2026 18:40
Source
Simply Wall Street
MarketBeat Direct company coverage

3 Biotech Firms With Major Potential Catalysts in the Coming Months

This article identifies three biotech firms, Vera Therapeutics (VERA), Krystal Biotech (KRYS), and ADMA Biologics (ADMA), that have significant potential catalysts in the near future. Vera and Krystal are clinical-stage companies awaiting key FDA decisions or data readouts for th

Tone
Positive 72/100
Event
Market update
Published
21 Jun 2026 14:10
Source
MarketBeat
Simply Wall Street Direct company coverage

3 US Pharmaceutical Stocks With Strong Margins And Earnings Growth

This article examines how the US Section 301 investigation into Germany's pharmaceutical pricing could impact American drug companies. It highlights three US pharmaceutical stocks—Krystal Biotech (KRYS), Kiniksa Pharmaceuticals International (KNSA), and Gilead Sciences (GILD)—tha

Tone
Positive 63/100
Event
Regulatory and legal
Published
19 Jun 2026 18:10
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus

Krystal Biotech (KRYS) is experiencing significant revenue growth and progress in its rare disease pipeline, particularly with VYJUVEK for dystrophic epidermolysis bullosa. The company's stock has seen substantial gains over the past year, attracting investor attention. While VYJ

Tone
Positive 73/100
Event
Earnings
Published
19 Jun 2026 00:10
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Krystal Biotech stock hits all-time high at 332.33 USD By Investing.com

Krystal Biotech (KRYS) stock reached an all-time high of $332.33, with a market capitalization of $9.74 billion, reflecting a 147.56% increase over the past year. The company's strong performance is supported by a 94% gross profit margin and an "EXCELLENT" financial health score.

Tone
Positive 94/100
Event
Earnings
Published
18 Jun 2026 11:10
Source
Investing.com Nigeria
TradingKey Direct company coverage

Krystal Biotech Inc (KRYS) Institutional Confidence

Krystal Biotech Inc (KRYS) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. Institutional ownership stands at 110.59%, an 11.17% increase quarter-over-quarter. Fidelity Management & Research C

Tone
Positive 73/100
Event
Market update
Published
18 Jun 2026 03:09
Source
TradingKey
TradingKey Direct company coverage

Krystal Biotech Inc (KRYS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Krystal Biotech Inc (KRYS), identifying major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdin

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

Krystal Biotech Inc (KRYS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Krystal Biotech Inc (KRYS) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis

Krystal Biotech Inc (KRYS) has a current valuation score of 7.41, placing it 241 out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio stands at 44.11, significantly lower than its recent high but above its recent low. The article notes that relevant data for

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
TradingKey
AlphaStreet Direct company coverage

Krystal Biotech Jumps 5.8% Amid Sector-Wide Rally

Krystal Biotech (KRYS) saw its shares climb 5.8% to $342.16, participating in a broader rally across the biotechnology sector. The increase was observed alongside similar gains in other biotech companies, suggesting a renewed investor interest in the sector rather than specific c

Tone
Positive 72/100
Event
Market update
Published
17 Jun 2026 18:40
Source
AlphaStreet
Investing.com Direct company coverage

Krystal Biotech stock hits all-time high at 332.33 USD

Krystal Biotech Inc.'s stock reached an all-time high of 332.33 USD, reflecting a 147.56% increase over the past year and a market capitalization of $9.74 billion, driven by strong investor confidence and an "EXCELLENT" financial health score. The company recently reported exceed

Tone
Positive 73/100
Event
Market update
Published
17 Jun 2026 09:51
Source
Investing.com
Stock Traders Daily Direct company coverage

Understanding the Setup: (KRYS) and Scalable Risk

This article analyzes Krystal Biotech Inc. (NASDAQ: KRYS), noting strong sentiment and an exceptional 32.7:1 risk-reward setup, targeting a 9.5% gain versus 0.3% risk. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for dif

Tone
Positive 73/100
Event
Market update
Published
16 Jun 2026 11:10
Source
Stock Traders Daily
TradingKey Direct company coverage

Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Krystal Biotech Inc (KRYS) has an earnings forecast score of 8.67, placing it 77th in its industry. Analysts have assigned a consensus "Buy" rating with an average target price of $218.00. The company's expected revenue for the next quarter is $125.62M, with anticipated EPS of $1

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 09:10
Source
TradingKey
Investor's Business Daily Direct company coverage

Stocks Jump As Trump Touts Iran Deal: SiTime, Krystal Biotech, Howmet In Focus

The stock market saw indexes jump on June 11, 2026, following former President Trump's comments about an Iran deal. This report highlights the day's market action with Alissa Coram and Ken Shreve discussing key stocks such as SiTime, Krystal Biotech, and Howmet Aerospace. The art

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 Jun 2026 16:47
Source
Investor's Business Daily
Investing.com India Direct company coverage

Krystal Biotech stock hits all-time high at 319.6 USD

Krystal Biotech (KRYS) stock reached an all-time high of $319.60, currently trading at $318.08 with a market capitalization of $9.37 billion. The company has seen a 124% increase in its stock price over the past year, driven by strong gross profit margins of 94% and a healthy bal

Tone
Positive 72/100
Event
Earnings
Published
10 Jun 2026 17:40
Source
Investing.com India
Simply Wall Street Direct company coverage

KRYS: Future Returns Will Reflect UK Approval And Mixed Execution Debate

Krystal Biotech's analyst price targets have seen modest adjustments, reflecting both optimism and caution among analysts. Bullish reports highlight confidence in current valuations and execution, while bearish views concern over-optimistic valuations and execution risks. The com

Tone
Positive 65/100
Event
Analyst action
Published
10 Jun 2026 06:10
Source
Simply Wall Street
TradingView Direct company coverage

Cash per share of Krystal Biotech, Inc. – MUN:4KB

This article provides financial information for Krystal Biotech, Inc. (MUN:4KB), specifically focusing on its cash per share. The content appears to be a stub or a section within a larger financial data platform, indicating where to find financial metrics for the company on the M

Tone
Neutral 50/100
Event
Balance sheet
Published
10 Jun 2026 00:10
Source
TradingView
Simply Wall Street Direct company coverage

This Insider Has Just Sold Shares In Krystal Biotech

Krystal Biotech's founder, Krish Krishnan, recently sold US$7.6m worth of stock, reducing their holding by 1.7%. This was the largest insider sale in the past year, occurring at a price close to the current share price. While the sale raises some caution, the company remains prof

Tone
Negative 40/100
Event
Market update
Published
09 Jun 2026 11:09
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing

An insider at Krystal Biotech (NASDAQ: KRYS) has sold shares valued at $7,702,984, as detailed in a recent SEC filing. The company is a commercial-stage biotechnology firm focused on developing genetic medicines for diseases with high unmet needs, including its approved product V

Tone
Negative 40/100
Event
Market update
Published
08 Jun 2026 07:40
Source
www.marketscreener.com
Yahoo! Finance Canada Direct company coverage

Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?

Krystal Biotech (KRYS) is presented as a strong investment due to its gene therapy platform for rare diseases, highlighted by its commercialized product VYJUVEK and a robust pipeline across multiple indications. The article emphasizes the potential for significant growth, recurri

Tone
Positive 77/100
Event
Market update
Published
07 Jun 2026 17:18
Source
Yahoo! Finance Canada
TradingView Direct company coverage

Krystal Biotech, Inc. Balance Sheet – XETR:4KB

Krystal Biotech, Inc.'s balance sheet for Q1 2026 shows total assets of 1.21 billion EUR, a 6.47% increase from Q4 2025. Total liabilities also rose by 7.00% to 104.07 million EUR in the first quarter of 2026. This article provides a snapshot of the company's financial position a

Tone
Positive 62/100
Event
Earnings
Published
06 Jun 2026 18:09
Source
TradingView
TradingView Direct company coverage

Krystal Biotech, Inc. Cash Flow – XETR:4KB

This article provides key cash flow metrics for Krystal Biotech, Inc. (XETR:4KB). It highlights that the free cash flow for Q1 2026 was €63.39 million, while for 2025, it stood at €160.84 million with an operating cash flow of €171.02 million. The data is presented in EUR and inc

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jun 2026 18:09
Source
TradingView
Investing.com Direct company coverage

Krystal Biotech CEO Krishnan sells $7.7m in company stock

Krystal Biotech CEO Krishnan sold approximately $7.7 million worth of company stock through a pre-arranged trading plan. This sale involved 25,000 shares, occurring while the company's stock trades near its 52-week high after a 127% return over the past year. Despite the sale, In

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 16:40
Source
Investing.com
Stock Titan Direct company coverage

Krystal Biotech (KRYS) CEO trades 25,000 shares under 10b5-1 plan

Krystal Biotech's President and CEO, Krish S. Krishnan, sold 25,000 shares of common stock on June 4, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. The sales were executed in multiple trades at weighted average prices between $300.75 and $312.23 p

Tone
Negative 33/100
Event
Market update
Published
06 Jun 2026 16:10
Source
Stock Titan
Stock Titan Direct company coverage

25K-share sale by Krystal Biotech (NASDAQ: KRYS) R&D head

Krystal Biotech's President of R&D, Suma Krishnan, sold 25,000 shares of common stock on June 4, 2026, through multiple open-market transactions. These sales, valued at approximately $7.7 million, were conducted under a pre-established Rule 10b5-1 trading plan. Krishnan also main

Tone
Negative 29/100
Event
Market update
Published
06 Jun 2026 04:09
Source
Stock Titan